Company news

Caris Life Sciences, Inc. (NASDAQ:CAI) news

Caris Life Sciences, Inc. news releases on 6ix. Latest, Sep 8, 2026: Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise…

Caris Life Sciences, Inc. (NASDAQ:CAI) news

Press releases & updates

Caris Life Sciences Launches New National Commercial Featuring Kevin Costner to Raise Awareness of Early Cancer Detection and Caris Detect

Caris Life Sciences to Present New Research Advancing Precision Oncology at the IASLC 2026 World Conference on Lung Cancer

Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer

Caris Life Sciences Reports Second Quarter 2026 Financial Results and Increases 2026 Revenue Guidance

Caris Life Sciences to Report Second Quarter 2026 Financial Results on August 5, 2026

Caris Life Sciences Expands Precision Oncology in Metastatic Prostate Cancer with PTEN IHC Testing

Caris Life Sciences Announces Dual Listing on NYSE Texas

Caris Life Sciences Announces Share Repurchase Program

Caris Life Sciences Launches Behind the Diagnosis Campaign Spotlighting Patient Lives Transformed by Caris' Comprehensive Genomic Testing

Caris Life Sciences Publishes Study on the Caris Lookback Program Demonstrating the Ongoing Clinical Value of Comprehensive Testing with Caris MI Cancer Seek

Caris Life Sciences Publishes Study Showing Whole Exome Measurement of Tumor Mutational Burden Results in Increased Overall Survival Compared to Estimates from Targeted Gene Panels

Caris Life Sciences Submits Application to New York State Department of Health for Caris Assure Blood‑Based Testing Authorization

Caris Life Sciences Reports First Quarter 2026 Financial Results

Caris Life Sciences Launches Caris MI Clarity, the First and Only AI-Powered Test to Predict Both Early and Late Distant Recurrence Risk in Breast Cancer at the Time of Diagnosis

Caris Life Sciences Receives MolDX Approval for Caris ChromoSeq, Advancing Access to Comprehensive Genomic Profiling for Myeloid Malignancies

Caris Life Sciences Publishes Study Validating Caris AI Insights for Temozolomide Benefit in Glioblastoma Patients

Caris Life Sciences to Present at the BofA Securities 2026 Health Care Conference and the Goldman Sachs 47th Annual Global Healthcare Conference

Caris Life Sciences to Report First Quarter 2026 Financial Results on May 7, 2026

Caris Precision Oncology Alliance Welcomes UCSF Helen Diller Family Comprehensive Cancer Center

Caris Life Sciences Right-In-Time Clinical Trial Solution Expands Access to Precision Oncology Trials for Historically Underserved Cancer Patients

Caris Life Sciences Introduces Multimodal AI-Powered Molecular Insight to Identify the Benefit or Harm from the Addition of Chemotherapy for NSCLC Patients

Caris Life Sciences Announces Launch of Caris ChromoSeq, the World's First Whole Genome and Whole Transcriptome Tumor Profiling Assay for Myeloid Malignancies

Caris Life Sciences Finalizes Achieve 1 Study Results Reinforcing the Superior Sensitivity and Specificity of Caris Detect

Caris Life Sciences Advances Precision Oncology with New AI Insights Predicting Brain Metastases Risk in Breast and Lung Cancer

Caris Life Sciences to Present Six Oncology Studies Utilizing Proprietary Multimodal Data at the AACR Annual Meeting 2026

Caris Life Sciences Highlights the Importance of DPYD Testing in Colorectal Cancer During Colorectal Cancer Awareness Month

Caris Life Sciences Announces Another Breakthrough Study for GPSai in Identifying and Correcting Misdiagnosis of Cancer Patients

Caris Life Sciences Introduces Powerful New Caris AI Insights to Identify Early Platinum Resistance in Ovarian Cancer

Caris Life Sciences to Showcase Five Studies at the 2026 USCAP Annual Meeting

Caris Life Sciences Launches a Novel Caris AI Insights Signature to Guide First-Line Therapy Selection and Treatment De-Escalation in Pancreatic Cancer

Caris Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides 2026 Outlook

/C O R R E C T I O N -- Caris Life Sciences/

Caris Launches Proprietary AI Insights Signature Which Deepens Understanding of Response to Breast Cancer Patients' Oral Chemotherapy Drug

Caris Life Sciences to Participate in the TD Cowen 46th Annual Health Care Conference

Caris Life Sciences to Report Fourth Quarter and Full Year 2025 Financial Results on February 26

Caris Life Sciences' Real-World Data Uncovers Metastatic Breast Cancer Patient Responses and Resistance to Trastuzumab Deruxtecan

Capstreet-backed Informativ Names Dominic Brignola as Chief Financial Officer

Caris Life Sciences Partners with Everlywell to Launch Caris' Forthcoming MCED Assay, Caris Detect

Caris Life Sciences Announces Preliminary Fourth Quarter and Full Year 2025 Results

Caris Life Sciences to Present at the 44th Annual J.P. Morgan Healthcare Conference

The Caris Precision Oncology Alliance Welcomes Providence Swedish Cancer Institute

Caris Life Sciences Announces Collaboration with Genentech to Discover Novel Therapeutic Targets in Cancers with High Unmet Clinical Need

Caris Life Sciences to Showcase 19 Studies at the 2025 San Antonio Breast Cancer Symposium

The Caris Precision Oncology Alliance Welcomes UAMS Winthrop P. Rockefeller Cancer Institute

Caris Precision Oncology Alliance Fellows Forum Welcomes 2025/2026 Class

Caris Life Sciences to Attend Q4 2025 Investor Conferences

Caris Life Sciences Reports Third Quarter 2025 Financial Results and Increases 2025 Revenue Guidance

Caris Data Validates TET2 Clonal Hematopoiesis as a Biomarker for Enhanced Immunotherapy Response

Caris Life Sciences to Report Third Quarter 2025 Financial Results on November 5, 2025

Caris Life Sciences to Share Six Collaborative Studies at ESMO 2025